Human cytochrome P450 1B1 (CYP1B1) plays a critical role in the metabolic activation of a variety of procarcinogens, including 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP). The existence of human CYP1B1 missense genetic variants has been demonstrated, but their activities in metabolizing PhIP are unknown. In this study, we expressed 15 naturally occurring CYP1B1 variants (with either single or multiple amino acid substitutions) and determined their activity changes in metabolizing PhIP to its two major metabolites, 2-hydroxyamino-PhIP and 4-hydroxy-PhIP. 
The estimated daily exposure of an individual to heterocyclic amines (HCAs) ranges from nanograms to a few micrograms (Augustsson et al., 1999) . 2-Amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP) is the most mass abundant HCA formed in meat and fish during hightemperature cooking as a result of the pyrolysis of amino acids and proteins (Sugimura and Sato, 1983) . Tobacco smoke is another major source of PhIP (Hecht, 2002) . PhIP has been found in the urine of healthy volunteers eating a normal diet (Ushiyama et al., 1991) , and PhIP-related DNA adducts have been detected in the urine of smokers (Peluso et al., 1991) . These results suggest that humans are ubiquitously exposed to PhIP. PhIP is mutagenic in bacterial and mammalian cells (Edwards et al., 1994; Hammons et al., 1997) . It induces colon, mammary gland, and prostate tumors in rats and T-cell and B-cell lymphoma in mice (Malfatti et al., 1999; Guengerich 2000; Williams et al., 2000; Ochiai et al., 2002; Nakagama et al., 2005) . Epidemiological studies suggest that colon cancer risk is increased in persons who consume high levels of mutagens in cooked meat (Gunter et al., 2005) . The National Toxicology Program concludes that PhIP is "reasonably anticipated to be a human carcinogen" (http://ntp.niehs.nih.gov/ntp/roc/eleventh/reason.pdf).
Like most environmental carcinogens, PhIP requires metabolic activation to exert its carcinogenic effects. The metabolism of PhIP leads to the formation of two major metabolites: 2-hydroxyaminoPhIP (N 2 -OH-PhIP) and 4Ј-hydroxy-PhIP (4Ј-OH-PhIP) (Shirai et al., 1997; King et al., 1999) (Fig. 1) . N 2 -OH-PhIP is highly mutagenic in both bacterial and mammalian cells, and its N-acetylated and -sulfated conjugates can form DNA adducts. In contrast, 4Ј-OH-PhIP is considered to be noncarcinogenic and is eventually excreted through urine after its conjugation with glucuronide or sulfate (Crofts et al., 1997) . The metabolic activation of PhIP (i.e., N-hydroxylation) is primarily catalyzed by the enzymes belonging to the cytochrome P450 (P450) 1 family, including CYP1B1 (Crofts et al., 1997) . Human CYP1B1 is constitutively expressed in many extrahepatic tissues and often overexpressed in a variety of human cancers (Murray et al., 1997) . In addition to PhIP, it catalyzes the activation of some other environmental carcinogens including arylarenes, nitroarenes, arylamines, and polycyclic aromatic hydrocarbons (Shimada et al., 1997) . Recently, the existence of the genetic variants of human CYP1B1 has been dem-onstrated (Stoilov et al., 1998; McLellan et al., 2000; Aklillu et al., 2002; Tanaka et al., 2002) . Functional characterization of several CYP1B1 missense variants has been conducted with carcinogen substrates estradiol, benzo [␣]pyrene, and 7,12-dimethylbenz[␣] anthracene (Li et al., 2000; Shimada et al., 2001; Aklillu et al., 2002; Aklillu et al., 2005) . However, the impact of these and other reported CYP1B1 missense variations on PhIP metabolism is yet unknown. It is important to emphasize that an alteration in catalytic function, induced by amino acid substitution, of a particular enzyme could be substrate-dependent. For example, while in comparison with the Val 432 form of CYP1B1, the Leu 432 form was reported to have a 3-fold increase in the K m value for estradiol hydroxylation but little effect on benzo[␣]pyrene epoxidation (Li et al., 2000) .
In the present study, we used a heterologous system to express a total of 15 naturally occurring CYP1B1 variant proteins (with either single or multiple amino acid substitutions) (Table 1 ) and compared them with the wild-type CYP1B1 protein in metabolizing PhIP to its major metabolites, N 2 -OH-PhIP and 4Ј-OH-PhIP. Our results are expected to provide direct evidence for the functional significance of these genetic variations in CYP1B1-mediated PhIP metabolism.
Materials and Methods

Materials. PhIP and N
2 -OH-PhIP were purchased from Toronto Research Chemicals (Toronto, ON, Canada). For standard validation, we also obtained N 2 -OH-PhIP as a gift from NCI Chemical Carcinogen Repository Midwest Research Institute (Kansas, MI). 4Ј-OH-PhIP was a generous gift from Dr. K. S. Kulp and Dr. M. G. Knize (Lawrence Livermore National Laboratory, Livermore, CA). Glucose 6-phosphate, glucose-6-phosphate dehydrogenase, NADP ϩ , ␦-aminolevulinic acid, ferric citrate, and HPLC grade methanol were purchased from Sigma-Aldrich (St. Louis, MO). Bac-to-Bac baculovirus expression system (including pFastbac1 expression vector) and Grace insect cell culture medium were obtained from Invitrogen (Carlsbad, CA). NADPH-P450 oxidoreductase was purified from rat liver microsomes as described previously (Yasukochi and Masters, 1976) . A polyclonal rabbit anti-human CYP1B1 antibody was obtained from Gentest Corp. (Boston, MA). Goat anti-rabbit IgG horseradish peroxidase conjugate was obtained from Bio-Rad (Hercules, CA). The ECL-enhanced chemiluminescence reagents for immunoblotting detection were obtained from Amersham Biosciences Inc. (Piscataway, NJ). KOD Hot Start DNA Polymerase was obtained from Novagen (Madison, WI).
Construction of CYP1B1 Variant cDNAs. The wild-type human CYP1B1 cDNA (NM_000104) was used as a template to generate the variant cDNAs by site-directed mutagenesis as described previously (Han et al., 2006) . The polymerase chain reaction primer sequences for the mutagenesis are shown in Table 2 . Additional rounds of mutagenesis were conducted to generate the variant cDNAs containing more than one nucleotide variations. All the variant cDNAs were sequenced after mutagenesis to ensure there were no extra mutations produced during polymerase chain reaction amplification process.
Heterologous Expression and Microsome Preparation. A Bac-to-Bac baculovirus expression system was used for the expression of CYP1B1 proteins. Wild-type and variant cDNAs were individually subcloned into the expression vector pFASTbac1. The reconstructed bacmid DNAs obtained after DNA transpositions in DH10B AC cells were transfected into Sf9 cells to obtain the recombinant baculovirus particles. Sf9 cells were subsequently infected in large scale with the virus particles for the production of the CYP1B1 proteins. ␦-Aminolevulinic acid and ferric citrate stock solutions (100 mM each, dissolved in Grace medium) were added to the culture medium for a final concentration of 100 M. The infected Sf9 cells were harvested 72 h after infection and resuspended in phosphate-buffered saline containing 5 mM imidazole, 20% glycerol, and 1 mM freshly added phenylmethylsulphonyl fluoride. Microsomes were prepared from the cells by sonication and differential centrifugation as previously described (Hong et al., 1999) . The microsome preparations were stored at Ϫ70°C before use. Protein concentrations were determined by the protein assay reagents from Bio-Rad.
Immunoblot Analysis and P450 Content Determination. Microsomal proteins (1 g) were loaded onto 10% SDS-polyacrylamide gels for electrophoresis and transferred to a nitrocellulose membrane. The membrane was blocked for 1 h using 5% (w/v) evaporated milk in Tris-buffered saline containing 0.0005% (v/v) Tween 20. The membrane was probed with a CYP1B1-specific polyclonal antibody (1:3300 dilution) as the primary antibody for 1 h and followed by goat anti-rabbit IgG, conjugated with horseradish peroxidase (1:5000 dilution), as the secondary antibody for 1 h. The immunoblot was visualized by ECL reagents according to the manufacture's protocol (Amersham Biosciences Inc.). Microsomal P450 content was determined by reduced CO-difference spectrum using a UV/visible spectrophotometer as previously described (He et al., 2004) .
PhIP Metabolism and Kinetic Analysis. The incubation mixture for PhIP metabolism consisted of 100 mM sodium phosphate buffer (pH 7.4), 5 mM MgCl 2 , an NADPH generating system (15 mM glucose 6-phosphate, 1 unit of glucose-6-phosphate dehydrogenase, 1 mM NADP ϩ ), NADPH-P450 oxidoreductase (reductase/P450 ϭ 1:1 in molar ratio), 100 pmol of CYP1B1, and PhIP in a total volume of 1 ml. After a 5-min preincubation, the reaction was initiated with the NADPH generating system and incubated at 37°C for 30 min. The reaction was terminated by adding one volume of ice-cold methanol. The mixture was then centrifuged at 4°C and filtered. Samples were stored at Ϫ70°C prior to analysis by HPLC within 48 h after the preparation. For the determination of kinetic parameters, eight different PhIP concentrations, ranging from 0.3 to 50 M, were used for incubation. The selection of substrate concentrations for activity assay and the determination of kinetic parameters were based on literature (Crofts et al., 1997) 
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HPLC Analysis. PhIP metabolites were analyzed using an HPLC-fluorescence system (Thermo Separation Products Inc., Fremont, CA) consisting of Spectra Physics P4000 Mobile Phase Pump, Spectra Physics AS3000 Autosampler, Spectra Physics FL2000 Fluorescence Detector, a Waters (Milford, MA) Bondapak C18 column (3.9 ϫ 300 mm, 125 Å, 10 m), a guard cartridge (Bondapak, 125 Å, 10 m), and software PC1000 for data collection and analysis. The metabolites were eluted with 55% methanol in water containing 0.1% diethylamine (pH 4.0 with acetic acid). The isocratic solvent was held at a flow rate of 1.25 ml/min for 20 min. The sample injection volume was 100 l. The excitation wavelength was 316 nm, and the emission wavelength was 370 nm. The analytical protocol was able to clearly resolve N 2 -OH-PhIP and 4Ј-OH-PhIP in less than 20 min. Concentrations of the PhIP metabolites were determined by calibration curves prepared using a standard solution of N 2 -OH-PhIP and 4Ј-OH-PhIP. Under our analytical conditions, the limits of detection were 0.02 pg for N 2 -OH-PhIP and 3.2 pg for 4Ј-OH-PhIP. For the validation of HPLC analysis, we used PhIP metabolite standards as well as the positive control and negative control samples from the in vitro metabolism.
Results
Heterologous Expression of the Wild-Type and Variant CYP1B1 Proteins. All the variant CYP1B1 cDNAs were successfully constructed and used for protein expression in the Bac-to-Bac baculovirus/Sf9 insect cell system. For most of the variant proteins, immunoblot analysis of the microsomal proteins detected a single pro- (Fig. 2A) . The Pro 437 Leu variant showed a substantial amount of expressed CYP1B1 protein but no detectable P450 peak (Fig. 2B ). All these results were confirmed by 3 to 5 independent expression experiments in the Sf9 cells. For the CYP1B1 variants with significantly lower levels of P450 content, the repeated expressions started from the expression vector reconstruction.
Activity of CYP1B1 Variants and Enzyme Kinetics. The formation of N 2 -OH-PhIP and 4Ј-OH-PhIP during CYP1B1-mediated PhIP metabolism was determined by a reported HPLC-fluorescence method (Crofts et al., 1997) . We modified the original protocol by changing gradient elution (from 33 to 55%) to isocratic elution with 55% FIG. 2. Heterologous expression of human CYP1B1 cDNAs in Sf9 cells. Microsomal proteins were prepared from the Sf9 cells infected for 72 h with recombinant bacmids containing either wild-type or variant CYP1B1 cDNAs. A, immunoblot analysis. Microsomal proteins (1 g) of each sample were used for electrophoresis. The membrane was probed with a CYP1B1-specific polyclonal antibody as the primary antibody, followed by goat anti-rabbit IgG conjugated with horseradish peroxidase as the secondary antibody for 1 h. Microsomes from the Sf9 cells transfected with the pFASTBAC1 vector alone (without CYP1B1 cDNA) were used as a negative control (Ϫ). B, representative CO-difference spectra. The assay solution containing microsomal proteins (2 g/l) was bubbled with CO for 60 s followed by addition of dithionite into the test cuvette and gentle mixing. The absorption spectrum was recorded from 500 to 400 nm. Microsomes prepared from the Sf9 cells expressing wild-type CYP1B1 and the Ser 119 and Trp 469 variants showed the characteristic P450 absorption peak, whereas the Leu 437 only displayed a major absorption peak at 420 nm. wt, wild-type. methanol. This change resulted in a satisfactory resolution of PhIP, N 2 -OH-PhIP, and 4Ј-OH-PhIP in less than 20 min instead of 40 min in the original method, which reduced the possibility of metabolite degradation when a large number of samples were analyzed. As shown in Fig. 3 , the retention times of N 2 -OH-PhIP, PhIP, and 4Ј-OH-PhIP are 4, 8, and 13 min, respectively.
When PhIP was incubated with microsomes containing wild-type CYP1B1, the production of N 2 -hydroxy PhIP and 4Ј-hydroxy PhIP was linear up to a 60-min incubation time and up to 120 pmol CYP1B1/ml reaction volume (data not shown). We therefore conducted the PhIP-metabolizing activity assay using a 30-min incubation time and 100 pmol CYP1B1/ml reaction volume. For the CYP1B1 variants with no detectable activity, the assay was repeated with increased amount of microsomal proteins (20-fold higher than the wild-type CYP1B1). The activity was determined at both high (10 M) and low (1 M) substrate concentrations. Figure 4 shows Gly. The kinetics of PhIP metabolism were determined with eight different substrate concentrations, ranging from 0.3 to 50 M. The experiments were always conduced in duplicate and showed less than 10% of assay variations (data not shown). When different concentrations of PhIP were incubated with the microsomes containing the wild-type human CYP1B1, the rate of formation of N 2 -OH-PhIP and 4Ј-OH-PhIP was initially linear but reached saturation at the PhIP concentrations above 10 M. The values of apparent K m and V max and catalytic efficiency (V max /K m ) derived from the kinetics curves are shown in Table 4 . The K m and V max values for both N-hydroxylation and 4-hydroxylation of PhIP by wild-type CYP1B1 in our kinetics study are consistent with the reported values (Crofts et al., 1997 
Discussion
Although previous studies demonstrated that human CYP1A2 is the major enzyme in the metabolic activation of PhIP, it is mainly expressed in the liver (Shimada et al., 1996) . In contrast, CYP1B1 is predominantly expressed in extrahepatic tissues, including prostate, mammary gland, and colon (Aklillu et al., 2005) . Therefore, metabolic activation of PhIP in situ by CYP1B1 and other extrahepatic enzymes such as CYP1A1 is believed to play a critical role in PhIP-related carcinogenesis in these tissues, such as prostate cancer (Holme et al., 1989; Patterson and Murray, 2002) . Because the amino acid substitutions in the CYP1B1 protein induced by genetic variations may alter the enzyme activity and/or protein stability, the present study characterized the functional significance of 15 CYP1B1 genetic variants in PhIP metabolism. As a result, we identified several CYP1B1 missense variants with changes in protein expression level and/or catalytic activity.
The microsomal CYP1B1 protein level was not detectable for the Asn 453 Ser variant and was significantly reduced for the Gly 365 Trp, Glu 387 Lys, and Arg 390 His variants. These CYP1B1 variants also lost their activity in both N-hydroxylation and 4-hydroxylation of PhIP. Based on a published computer modeling study (Stoilov et al., 1998) , Gly 365 belongs to the conserved core structures of CYP1B1. Substitution of Gly 365 with Trp may interfere with the proper folding and heme-binding of CYP1B1 protein. Both Glu 387 and Arg 390 residues of CYP1B1 are localized in the conserved helix K, which are one helical turn apart and are predicted to form a salt bridge. Substitutions with Lys and His at these locations probably alter the secondary structure of CYP1B1 protein, which may affect the enzyme in its coupling with NADPH-cytochrome P450 reductase and catalytic function. The lack of detectable Asn 453 Ser variant protein in our observation is consistent with a recent study in which there was a significant decrease in the level of Asn 453 Ser variant protein transiently expressed in the COS-1 cells (Bandiera et al., 2005) . The same authors also demonstrated that the degradation of the Asn 453 Ser variant protein by the FIG. 4 . PhIP N-hydroxylation and 4-hydroxylation activity of heterologously expressed wild-type and variant CYP1B1. The activity was determined at 10 M PhIP. The incubation mixture for PhIP metabolism consisted of 100 mM sodium phosphate buffer (pH 7.4), 5 mM MgCl 2 , and an NADPH generating system. After a 5-min preincubation, the reaction was initiated with the NADPH generating system and NADPH-P450 oxidoreductase incubated at 37°C for 30 min. 
Kinetic parameters for PhIP N-hydroxylation and 4-hydroxylation by human CYP1B1
The values are the average of duplicated experiments with less than 10% variation.
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Variants at ASPET Journals on September 6, 2017 dmd.aspetjournals.org proteasomal pathway is much faster than the wild-type CYP1B1 protein (Bandiera et al., 2005) , suggesting that the substitution of Asn 453 with Ser leads to an unstable protein structure. In contrast to a reported finding that the Gly 61 Glu variant has a greatly diminished protein stability when it is expressed in Escherichia coli (Jansson et al., 2001 ), we did not observe a significant change in protein content of this CYP1B1 variant in our expression system.
It is of interest to observe that both the Pro 437 Leu and Arg 469 Trp variants showed the same protein expression levels in the microsomes as the wild-type CYP1B1 but lost the PhIP-metabolizing activity. However, the involved inactivation mechanisms for these two variants are apparently different. The Pro 437 Leu variant protein lacks the characteristic P450 absorption peak in CO-difference spectrum analysis, suggesting the amino acid substitution affects the heme binding. This may be explained by the modeling result that Pro 437 is localized in the meander region and precedes the heme binding region (Stoilov et al., 1998) . On the other hand, the P450 absorption peak was clearly present for the Arg 469 Trp variant, which is consistent with the observation of Jansson et al. (2001) that the stability of this variant protein was normal. As predicted by the same model (Stoilov et al., 1998) , Cys 470 in CYP1B1 is the cysteine that is completely conserved among all the microsomal cytochrome P450 enzymes and provides the axial heme ligand in the heme-binding region. Arg 469 immediately precedes Cys 470 and a replacement with Trp, a larger amino acid residue with a rigid side group, may interfere with the normal conformation of the highly conserved cysteine pocket and catalytic function.
According to the CYP1B1 model (Stoilov et al., 1998) , Trp 57 is located in a hinge region and precedes the last proline residue of the hinge. As one of the most conserved amino acid residues in the same region, Gly 61 is also very close to the proline. Previous studies revealed that substitution of the corresponding proline residue in CYP2C11 and CYP2C2 could influence heme incorporation and reduce enzymatic activity (Yamazaki et al., 1993; Chen and Kemper, 1996) . Substitution of nonpolar and hydrophobic tryptophan with polar cysteine or replacement of noncharged glycine with charged glutamic acid in this hinge region may interfere with the proper folding of the CYP1B1 protein and result in decreased enzymatic activity as observed in PhIP metabolism.
The Gly (CYP1B1*7) exist as common haplotypes in several different populations (Aklillu et al., 2002; Aklillu et al., 2005) . During the enzyme kinetic study of the CYP1B1 variants with reduced PhIP-metabolizing activity, the variants Arg Ser variant (CYP1B1.2) showed no K m value change for PhIP N-hydroxylation and in the metabolism of other substrates (Aklillu et al., 2002; Aklillu et al., 2005) , it is reasonable to speculate that the K m value changes in the variants Arg Gly substitution in the CYP1B1.7 variant resulted in a further increase in the K m value for PhIP N-hydroxylation, suggesting that the substitution also affects substrate binding. In addition, the alteration of enzymatic function in CYP1B1 variants is clearly substrate-dependent. Although the capacity for N-hydroxylation of PhIP was significantly decreased in both CYP1B1.6 and CYP1B1.7 variants, a significantly decreased capacity for oxidation of benzo [␣] pyrene was only observed in the CYP1B1.7 variant, not in the CYP1B1.6 variant (Aklillu et al., 2005) .
In summary, the present study demonstrates that several genetic variants of human CYP1B1 have significant changes in the protein expression level and PhIP-metabolizing activity. These results appear to be consistent with the prediction of a published CYP1B1 protein model (Stoilov et al., 1998) . Our study provides new information on the role of involved amino acid residues in protein stability and catalysis of CYP1B1. In addition, identification of these functional CYP1B1 variants should help understand the interindividual variations in PhIP metabolism and their potential impact on the risk to human cancers related to PhIP exposure.
